Form 8-K - Current report:
SEC Accession No. 0001628280-25-033302
Filing Date
2025-06-27
Accepted
2025-06-27 16:03:51
Documents
14
Period of Report
2025-06-24
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K cdxc-20250624.htm   iXBRL 8-K 55335
2 EX-10.1 nage-2017equityincentivepl.htm EX-10.1 216414
3 EX-10.2 nage-employeestockpurchase.htm EX-10.2 84206
  Complete submission text file 0001628280-25-033302.txt   531414

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT cdxc-20250624.xsd EX-101.SCH 1776
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT cdxc-20250624_lab.xml EX-101.LAB 21689
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT cdxc-20250624_pre.xml EX-101.PRE 12519
16 EXTRACTED XBRL INSTANCE DOCUMENT cdxc-20250624_htm.xml XML 2735
Mailing Address 10900 WILSHIRE BLVD SUITE 600 LOS ANGELES CA 90024
Business Address 10900 WILSHIRE BLVD SUITE 600 LOS ANGELES CA 90024 310-388-6706
Niagen Bioscience, Inc. (Filer) CIK: 0001386570 (see all company filings)

EIN.: 262940963 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37752 | Film No.: 251086227
SIC: 2833 Medicinal Chemicals & Botanical Products
(CF Office: 03 Life Sciences)